<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20400350</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Enterovirus 71 vaccine: close but still far.</ArticleTitle><Pagination><StartPage>e739</StartPage><EndPage>e743</EndPage><MedlinePgn>e739-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2009.12.002</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus 71 (EV71), a member of the Enterovirus genus of the Picornaviridae family, is one of the causative pathogens of hand-foot-and-mouth disease (HFMD) and the most common etiological agent isolated from HFMD patients complicated with neurological disorders. EV71 has become an increasingly important neurotropic enterovirus in the post-poliomyelitis eradication era. Effective antiviral agents and vaccines against this virus are currently still under development. We reviewed publications on the development of EV71 vaccines in order to provide an overview of the field.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-five articles on EV71 vaccine development, published from 1974 to 2009, were collected from Sun Yat-sen University library and reviewed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Various types of vaccine have been developed for EV71. In results published to date, all vaccines for EV71 under development appear to elicit an immune response in rodents or in monkeys. According to the established regulatory standards, it may be relatively easy to acquire a license to use the inactivated virus in order to meet the immediate demands for EV71 control . With regard to the attenuated vaccine, it is critical to increase the genetic stability before clinical use, due to the risk of virulent revertants. The virus-like particle (VLP) vaccine, not only conserving the conformational epitopes, but also having no risk of virulent revertants, is another promising vaccine candidate for EV71, but needs further development. The VP1 capsid protein is the backbone antigen protein for developing subunit vaccine and epitope vaccine; these remain viable potential vaccine strategies worthy of further study and development.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The conservation of the three-dimensional structure is important for the EV71 inactivated vaccine and VLP vaccine to induce a strong immune response. To develop EV71 vaccines with a high protection efficacy, strategies such as the use of adjuvant, strong promoters, tissue-specific promoters, and addition of mucosal immune adjuvant should be considered.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dingmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Public Health, Sun Yat-sen University, Laboratory for Tropical Disease Control and Prevention, Guangdong Provincial Research Center for Severe Infectious Disease Prevention and Control Technology, Guangzhou 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jiayuan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jiahai</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20400350</ArticleId><ArticleId IdType="pmc">PMC7110504</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2009.12.002</ArticleId><ArticleId IdType="pii">S1201-9712(10)02313-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ishimaru Y., Nakano S., Yamaoka K., Takami S. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child. 1980;55:583&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1627055</ArticleId><ArticleId IdType="pubmed">6254449</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg J., Lycke E., Ahlfors K., Johnsson T., Wolontis S., von Zeipel G. Letter: New enterovirus type associated with epidemic of aseptic meningitis and-or hand, foot, and mouth disease. Lancet. 1974;2:112.</Citation><ArticleIdList><ArticleId IdType="pubmed">4136956</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagaya I., Takayama R., Hagiwara A. A large-scale epidemic of hand, foot and mouth disease associated with enterovirus 71 infection in Japan in 1978. Jpn J Med Sci Biol. 1981;34:191&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">6273621</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy G., Takatsy S., Kukan E., Mihaly I., Domok I. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982;71:217&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">6285858</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert G.L., Dickson K.E., Waters M.J., Kennett M.L., Land S.A., Sneddon M. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J. 1988;7:484&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">2841639</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuda G.M., Chang W.K., Yeung C.Y., Tang P.S. Monoplegia caused by Enterovirus 71: an outbreak in Hong Kong. Pediatr Infect Dis J. 1987;6:206&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">3562141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341:929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T., Chikahira M., Yoshida S., Ebira H., Hasegawa A., Totsuka A. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol. 2002;46:621&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">12437029</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Chow V.T., Phoon M.C., Chan K.P., Poh C.L. Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J Clin Microbiol. 2002;40:2823&#x2013;2827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC120643</ArticleId><ArticleId IdType="pubmed">12149336</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Outbreak news. Enterovirus, China. Wkly Epidemiol Rec 2008; 83:169&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18472450</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., Ren L., Xiong Z., Li J., Xiao Y., Zhao R. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol. 2009;47:2351&#x2013;2352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of health of the people's republic of China, Reports of National Notifiable Communicable Diseases. &lt;http://www.moh.gov.cn/publicfiles//business/htmlfiles/zwgkzt/pyq/list.htm&gt;.</Citation></Reference><Reference><Citation>Chen K.T., Chang H.L., Wang S.T., Cheng Y.T., Yang J.Y. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998&#x2013;2005. Pediatrics. 2007;120:e244&#x2013;e252.</Citation><ArticleIdList><ArticleId IdType="pubmed">17671037</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicklin M.J., Krausslich H.G., Toyoda H., Dunn J.J., Wimmer E. Poliovirus polypeptide precursors: expression in vitro and processing by exogenous 3C and 2A proteinases. Proc Natl Acad Sci U S A. 1987;84:4002&#x2013;4006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305009</ArticleId><ArticleId IdType="pubmed">3035560</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.C., Hsu J.T., Huang J.H., Ho M.S., Ho Y.C. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol Lett. 2003;25:919&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">12889824</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003;21:1769&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">12686092</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke P., Kitchin N., Souverbie F. A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim. Vaccine. 2001;19:4429&#x2013;4433.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483268</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., King C.C., Hsu K.H., Ning H.C., Tsao K.C., Li C.C. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002;109:e88.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.K., Chen C.C., Chen C.L., Wang J.R., Liu C.C., Yan J.J. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci. 2000;7:523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20:895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.C., Wu C.N., Shih S.R., Ho M.S. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine. 2002;20:2485&#x2013;2493.</Citation><ArticleIdList><ArticleId IdType="pubmed">12057603</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S.C., Liu C.C., Lian W.C. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine. 2004;22:3858&#x2013;3864.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364432</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Lian W.C., Butler M., Wu S.C. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine. 2007;25:19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul Y. Oral polio vaccines and their role in polio eradication in India. Expert Rev Vaccines. 2009;8:35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">19093771</ArticleId></ArticleIdList></Reference><Reference><Citation>John J. Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines. 2009;8:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19093765</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Shimizu H., Nagata N., Ami Y., Suzaki Y., Sata T. Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol. 2005;86(Pt 5):1391&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831951</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Ami Y., Wakita T., Shimizu H. Cooperative effect of the attenuation determinants derived from poliovirus Sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol. 2008;82:1787&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2258712</ArticleId><ArticleId IdType="pubmed">18057246</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Nagata N., Iwata N., Ami Y., Suzaki Y., Mizuta K. An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007;81:9386&#x2013;9395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamishi S., Shahmahmoudi S., Tabatabaie H., Teimourian S., Pourakbari B., Gheisari Y. Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. Eur J Pediatr. 2008;167:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">18317803</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards E.A., Grant C.C., Huang Q.S., Powell K.F., Croxson M.C. A case of vaccine-associated paralytic poliomyelitis. J Paediatr Child Health. 2000;36:408&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940185</ArticleId></ArticleIdList></Reference><Reference><Citation>The Department of Vaccines and Biologicals. Adverse events following poliomyelitis vaccine. In: Clements DC, editor. Supplementary information on vaccine safety. Geneva: World Health Organization; 2000, p.78.</Citation></Reference><Reference><Citation>Ho M. Enterovirus 71: the virus, its infections and outbreaks. J Microbiol Immunol Infect. 2000;33:205&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11269363</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas L., Clements J.D. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev. 1992;5:328&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC358247</ArticleId><ArticleId IdType="pubmed">1498769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Coppel R.L. Oral vaccine delivery: can it protect against non-mucosal pathogens? Expert Rev Vaccines. 2008;7:729&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">18665772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.F., Chang M.H., Chiang B.L., Jeng S.T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine. 2006;24:2944&#x2013;2951.</Citation><ArticleIdList><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.L., Huang J.Y., Chu T.W., Tsai T.C., Hung C.M., Lin C.C. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine. 2008;26:2882&#x2013;2889.</Citation><ArticleIdList><ArticleId IdType="pubmed">18450335</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu C.H., Chu C., He C.C., Lin T.Y. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect. 2006;8:1671&#x2013;1678.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Yang T., Sun Q.M., Sun M.S. Efficient intranasal immunization of newborn mice with recombinant adenovirus expressing rotavirus protein VP4 against oral rotavirus infection. Acta Virol. 2005;49:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15929394</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Wu W., Xu X. Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice. Vaccine. 2007;25:7664&#x2013;7673.</Citation><ArticleIdList><ArticleId IdType="pubmed">17913305</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F., Zhang Z.R., Yuan F., Qin X., Wang M., Huang Y. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int J Pharm. 2008;349:226&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">17825506</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 2000;18:927&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">10837079</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung W.S., Bakar S.A., Sekawi Z., Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Z., Baizer L., Mumper R.J. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol. 2003;102:105&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697387</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland J.R., Letvin N.L. Chemical adjuvants for plasmid DNA vaccines. Vaccine. 2007;25:3731&#x2013;3741.</Citation><ArticleIdList><ArticleId IdType="pubmed">17350735</ArticleId></ArticleIdList></Reference><Reference><Citation>Garmory H.S., Brown K.A., Titball R.W. DNA vaccines: improving expression of antigens. Genet Vaccines Ther. 2003;1:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC244903</ArticleId><ArticleId IdType="pubmed">14606963</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G., Macary P.A., Alonso S., Poh C.L. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol. 2008;21:215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">18419256</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G., Alonso S., Chow V.T., Poh C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Mao C., Ma S., Wang X., Sun Z., Yi Y. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun. 2009;390:1126&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">19799860</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L., Li Y., Cannon P.M., Kim S., Kang C.Y. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc Natl Acad Sci U S A. 1992;89:10527&#x2013;10531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50372</ArticleId><ArticleId IdType="pubmed">1438241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho Y., Lin P.H., Liu C.Y., Lee S.P., Chao Y.C. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun. 2004;318:833&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111196</ArticleId><ArticleId IdType="pubmed">15147946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.C., Huang J.H., Lai C.W., Sheng H.C., Shih S.R., Ho M.S. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol. 2006;12:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>